Effects of empagliflozin on serum uric acid level of patients with type 2 diabetes mellitus: a systematic review and meta‐analysis

Table 1 Characteristics of included studies

Author, year of publication	Country	Type of study	Sample size in empagliflozin group	Sample size in compare group	Mean age in empagliflozin group (year)	Mean age in compare group (year)	Duration of use	Dosage	Compare group
Schulze et al. 2022 [21]	Germany	RCT	30	29	72.9	76.05	4 weeks	25 mg	Placebo
Bogoviku et al. 2022 [19]	Germany	RCT	30	29	74.7	74.7	5 Day	25 mg	Placebo
Nesti et al. 2022 [28]	Italy	RCT	22	22	61.6	61.8	24 weeks	10 mg	Sitagliptin
Mozawa et al. 2021 [29]	Japan	RCT	46	50	63.9	64.6	24 weeks	10 mg	Placebo
Hiruma et al. 2021 [30]	Japan	RCT	21	21	52.8	47.8	12 weeks	10 mg	Sitagliptin
Okada et al. 2021 [20]	Japan	RCT	38	49	66	66	12 weeks	10 mg	Placebo
Okada et al. 2021 [20]	Japan	RCT	30	14	78.4	78.4	12 weeks	10 mg	Placebo
Shimizu et al. 2020 [31]	Japan	RCT	46	50	63.9	64.6	24 weeks	10 mg	Placebo
Gunhan et al. 2020 [32]	Turkey	Retrospective observational	70	49	56.46	56.46	24 weeks	NR	Dapagliflozin
Bosch et al. 2019 [33]	Germany	RCT	29	29	62	62	6-weeks	25 mg	Placebo
Inzucchi et al. 2018 [34]	USA	RCT	7020	NR	NR	NR	164 weeks	10 mg	Placebo
Inzucchi et al. 2018 [34]	USA	RCT	7020	NR	NR	NR	164 weeks	25 mg	Placebo
Yanai et al. 2017 [22]	Japan	Retrospective observational	15	20	51	52.3	12 weeks	25 mg	Dapagliflozin
Yanai et al. 2017 [22]	Japan	Retrospective observational	6	16	51	52.3	24 weeks	25 mg	Dapagliflozin
Heise et al. 2016 [35]	Germany	RCT	20	NR	56	NR	5 Day	25 mg	Placebo

ISSN: 1758-5996